Inventor
Sina FELLERMEIER-KOPF
Inventor
DE
Overview
Patents· 5 as inventor
Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.
A61Kprimary
A61KPreparations for medical, dental or toiletry purposes29%
A61PSpecific therapeutic activity of chemical compounds or medicinal preparations29%
C07KPeptides29%
C12NMicroorganisms or enzymes12%
PatentTitleYear
12,595,292Interleukin-2 receptor (IL2R) and interleukin-2 (IL2) variants for specific activation of immune effector cells202612,522,640IL2 agonists202612,410,258Antibodies capable of binding to OX40, variants thereof and uses thereof202512,398,214Binding agents binding to EpCAM and CD137202511,932,693Monoclonal antibodies directed against programmed death-1 protein and their use in medicine2024Career & activity timeline
Assembled from patent assignee/location history and declaration credentials.
2024–2026Patents assigned to BioNTech SE (4)· patent assignee history
2024–2025Patents assigned to GENMAB AS (3)· patent assignee history
2024–2026Based in DE· patent location history
2025Patents assigned to GANMAB AS (1)· patent assignee history
2026Patents assigned to BIONTECH CELL & GENE THERAPIES GMBH (1)· patent assignee history
2026Patents assigned to BIONTECH RNA PHARMACEUTICALS GMBH (1)· patent assignee history
Inventor activity
Assignee and location history derived from the patent record.
Assignees
| Assignee | Patents | Span |
|---|---|---|
| BioNTech SE | 4 | 2024–2026 |
| GENMAB AS | 3 | 2024–2025 |
| BIONTECH CELL & GENE THERAPIES GMBH | 1 | 2026 |
| BIONTECH RNA PHARMACEUTICALS GMBH | 1 | 2026 |
| GANMAB AS | 1 | 2025 |
Locations
| Location | Patents | Span |
|---|---|---|
| DE | 5 | 2024–2026 |